Read Time:12 Second
Jaguar Health Inc.’s stock tumbled 66% Tuesday, after the biotech said a late-stage trial of a drug that aims to prevent diarrhoea in cancer patients undergoing treatment failed to meet its main goal across all tumor types.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
